Skip to main content

Table 1 Correlation of MAP3K7/CASP8AP2 deletions with clinical features in primary T-ALL patients

From: MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB

Characteristic

 

MAP3K7/CASP8AP2 wildtype (%)

MAP3K7/CASP8AP2 deletion (%)

 

All

 

294 (100)

33 (100)

 

Sex

Male

213 (72.4)

27 (81.8)

p = 0.30

Female

81 (27.6)

6 (18.2)

 

Age

< 10

152 (51.7)

15 (45.5)

p = 0.58

≥10

142 (48.3)

18 (54.5)

 

WBC at diagnosis

< 10,000

26 (8.8)

2 (6.1)

p = 0.93

10,000–50,000

69 (23.5)

7 (21.2)

 

50,000–100,000

55 (18.7)

7 (21.2)

 

≥100,000

144 (49.0)

17 (51.5)

 

Mediastinal mass

Yes

155 (54.2)

16 (48.5)

p = 0.58

No

131 (45.8)

17 (51.5)

 

T-cell immunophenotypea

Early (Pro-/Pre-) T-ALL

89 (30.3)

7 (21.2)

p = 0.0005

Cortical T-ALL

177 (60.2)

16 (48.5)

 

Mature T-ALL

24 (8.2)

10 (30.3)

 

Prednisone response

PGR

173 (58.8)

17 (51.5)

p = 0.35

PPR

113 (38.4)

16 (48.5)

 

MRD on day 33

N/A

49 (16.7)

2 (6.1)

p = 0.18

Negative

54 (18.4)

4 (12.1)

 

10−4

76 (25.9)

7 (21.2)

 

≥10−3

115 (39.1)

20 (60.6)

 

MRD on day 78

N/A

42 (14.3)

2 (6.1)

p = 1.00

< 10−3

221 (75.2)

27 (81.8)

 

≥10−3

31 (10.5)

4 (12.1)

 

Risk Group 2000b

SR

41 (13.9)

3 (9.1)

p = 0.69

MR

127 (43.2)

14 (42.4)

 

HR

126 (42.9)

16 (48.5)

 

Genetics: SIL-TAL1 fusion

Yes

39 (13.2)

12 (36.4)

p = 0.002

No

255 (86.7)

21 (63.6)

 
  1. WBC White blood cell count, PGR/PPR Prednisone good/poor response, MRD Minimal residual disease, SR/MR/HR Standard/Medium/High risk. aEarly = Pro (cyCD3+, CD7+) and Pre (cyCD3+, CD2+ and/or CD5+ and/or CD8+); cortical (CD1a+); mature (CD1a−, sCD3+). cyCD3+: cytoplasmic CD3+; sCD3+: surface CD3+. bThe ALL-BFM 2000 overall risk classification defines three groups: SR - prednisone good response on day 8 (< 1000/μL leukemic blasts in peripheral blood) and complete cytomorphologic remission on day 33 and negative MRD on day 33 and day 78; MR - prednisone good response on day 8 and complete cytomorphologic remission on day 33 and MRD positive on day 33 and/or day 78, but < 10−3 on day 78; HR – prednisone poor response on day 8 or no complete cytomorphologic remission on day 33 or MRD on day 78 ≥ 10− 3 [3]
  2. If numbers for clinical data sum up to less than 327, this feature was not available for all patients
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us